You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Claims for Patent: 12,070,450

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,070,450

Title:	Treatment of migraine
Abstract:	The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Inventor(s):	Joel M. Trugman, Ramesh BOINPALLY, Abhijeet Jakate, Michelle Finnegan
Assignee:	Allergan Pharmaceuticals International Ltd
Application Number:	US18/523,481
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,070,450
Patent Claims:	1. A method for the acute treatment of migraine with or without aura in a patient undergoing treatment with a weak or moderate CYP3A4 inducer, the method comprising orally administering 100 mg ubrogepant to the patient, wherein the patient's migraine is safely and effectively treated. 2. The method of claim 1, comprising orally administering to the patient a second dose of 100 mg of ubrogepant at least 2 hours after the administration of the initial 100 mg of ubrogepant. 3. The method of claim 2, wherein the second dose is administered to the patient between 2 and 24 hours after the administration of the initial 100 mg of ubrogepant. 4. The method of claim 1, wherein the patient achieves freedom from at least one migraine symptom within 2 hours after the administration of said ubrogepant.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.